Palatin Technologies, Inc. (AMEX:PTN) will hold its 1Q21 earnings conference call with the financial community on 17th November 2020 at 11:00 AM Eastern Time.
The conference call will be webcast live on Internet at www.palatin.com
Alternatively, callers may dial the number(s) 1-800-353-6461 or 1-334-323-0501 Toll Number, when prompted, enter passcode 3383273
Earnings Expectation
Palatin Technologies, Inc. is reporting first quarter financial results on Tuesday 17th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, PTN is expected to report 1Q21 loss of $ 0.03 per share from revenue of $ 1.00 million. For the full year, analysts anticipate top line of $ 8.28 million, while looking forward to loss of $ 0.12 per share bottom line.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The companys principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders.
